Filip Janku's most recent trade in Monte Rosa Therapeutics Inc was a trade of 5,407 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 5,407 | 81,093 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.50 per share. | 30 Jun 2026 | 5,407 | 60,612 | - | 24.5 | 132,472 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.41 per share. | 30 Jun 2026 | 5,407 | 66,019 | - | 13.4 | 72,508 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.56 per share. | 29 Jun 2026 | 6,000 | 65,992 | - | 7.6 | 45,360 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 6,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.95 per share. | 29 Jun 2026 | 6,000 | 59,992 | - | 23.0 | 137,700 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 23 Jun 2026 | 30,000 | 59,992 | - | 21.4 | 642,681 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.56 per share. | 23 Jun 2026 | 30,000 | 89,992 | - | 7.6 | 226,800 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 30,000 | 66,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 23 Jun 2026 | 11,845 | 59,992 | - | 20.2 | 239,522 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.56 per share. | 23 Jun 2026 | 6,000 | 71,837 | - | 7.6 | 45,360 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 6,000 | 96,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 23 Feb 2026 | 9,189 | 65,837 | - | 19.5 | 179,161 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 139,000 | 139,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 31,000 | 78,181 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 02 Jan 2026 | 3,155 | 75,026 | - | 15.2 | 47,861 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 36,000 | 45,189 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Janku Filip | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 121,000 | 121,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 86,500 | 86,500 | - | - | Stock Option (Right to Buy) |